Pharmacogenomics presents the potential to tailor pharmacotherapy by pinpointing genetic differences linked to responses to medications, adverse effects and treatment efficacy. However, converting pharmacogenomic findings into everyday clinical use entails robust clinical decision-support systems and synchronized healthcare delivery. Pharmacogenomic notifications integrated into electronic health records can relay actionable gene-drug recommendations during prescribing, thus fostering safer and more appropriate drug selection. This review explores the function of pharmacists in the implementation of pharmacogenomic notifications, highlighting their roles in interpreting genetic results, reviewing medications, providing prescribing recommendations, counseling patients and collaborating across professions. Evidence from clinical implementation research suggests that pharmacogenomically informed prescribing can sway therapeutic choices and potentially decrease specific adverse drug reactions. However, clinical advantages vary based on gene-drug associations, implementation strategies, notification designs, clinician acceptance and healthcare environments. Ongoing challenges include a lack of pharmacogenomic knowledge, insufficient interoperability, alert fatigue, financial limitations, ambiguous professional responsibilities and uneven access to testing. Pharmacists can tackle various implementation obstacles through focused education, standardized processes, cooperative practice and systematic evaluation of outcomes. Future studies should determine the comparative effectiveness, cost-efficiency, sustainability and fairness of pharmacist-led services. Incorporating clinically relevant notifications into standard pharmacy practice may enhance precise pharmacotherapy and medication safety, while also promoting evidence-based, patient-centered prescribing across healthcare contexts.
Loading....